

University of California, San Francisco
CURRICULUM VITAE

Name: Chuanyi Mark Lu, MD

Position: Professor & Vice Chair
Laboratory Medicine
School of Medicine

Address: Mailbox: VAMC 113A
University of California, San Francisco
Voice: (415)750-2278
Fax: (415)750-6948
Email: mark.lu@va.gov
Web: <http://labmed.ucsf.edu/about/faculty/labmed-mlu.html>

EDUCATION

1983 - 1991	Tongji Medical University	MD, MSc	Medicine
1991 - 1994	Peking (Beijing) University Health Science Center	Lecturer & Staff Scientist	Pathophysiology & Cardiovascular Diseases
1994 - 1998	UC San Diego School of Medicine	Postdoctoral Fellow	Molecular and Cellular Biology
1998 - 2002	UC San Diego Hospitals	Resident	Pathology (Anatomic & Clinical)
2002 - 2003	Harvard Medical School/BIDMC	Clinical Fellow	Hematology & Hematopathology
2005 - 2006	UC San Francisco School of Medicine	Teaching Scholar	Teaching Scholars Program (TSP)

LICENSES, CERTIFICATION

1996	ECFMG Certificate, Educational Commission Foreign Medical Graduates (#0-552-787-4)
2000	Physician and Surgeon License , Medical Board of California (#A73318)
2002	Board Certificate: Clinical Pathology, American Board of Pathology (#02-373)
2003	Board Certificate: Hematology , American Board of Pathology (#S-03-175)
2015	MRO Certificate: Medical Review Officer Certification Council (MROCC) (#15-11396)

PRINCIPAL POSITIONS HELD

2003 - 2009	University of California, San Francisco, School of Medicine	Assistant Professor	Laboratory Medicine
2003 - 2020	VA Healthcare System, San Francisco	Chief, Hematology & Hematopathology	Laboratory Medicine Service
2009 - 2014	University of California, San Francisco, School of Medicine	Associate Professor	Laboratory Medicine
2014 - 2016	University of California, San Francisco, School of Medicine	Professor	Laboratory Medicine
2016 - present	University of California, San Francisco, School of Medicine	Clinical Professor	Laboratory Medicine
2017 - present	VA Healthcare System, San Francisco	Chief, Lab Medicine Service (CLIA Lab Director)	Laboratory Medicine
2017 - present	University of California, San Francisco, School of Medicine	Vice Chair	Laboratory Medicine
2019 - present	San Francisco VA Healthcare System	Lead, Diagnostic Service Line (Pathology, Lab Medicine and Radiology)	

OTHER POSITIONS HELD CONCURRENTLY

2003 - present	VA Healthcare System, San Francisco	Staff Physician (Attending)	
2004 - 2017	UCSF Department of Laboratory Medicine	Site Director, Laboratory Medicine Residency Program	
2003 - 2017	UCSF Medical Center	Attending (Hematology & Hematopathology)	
2009 - present	VA Healthcare System, San Francisco	Director, Clinical Laboratory Scientist (CLS) Training Program	
2011 - present	VA Healthcare System, San Francisco	Director, Molecular Diagnostics, Lab Medicine Service	

2015 - present	VA Healthcare System, San Francisco	Medical Review Officer (MRO)
2017 - present	VA Healthcare System, San Francisco	Director, Clinical Chemistry
2015 - present	San Francisco State University	Faculty, Biological Sciences
2016 - 2019	University of California Berkeley	Faculty, UCB Extension Program
2017 - present	University of San Francisco	Faculty, Biological Sciences

HONORS AND AWARDS

1995	Trainee Investigator Award	American Society of Clinical Research & Am. Federation for Medical Research
1998	Specialty Research Award	American Federation for Medical Research
2000	National Research Service Award (NRSA)	National Institutes of Health (NIH)
2001	National Research Service Award (NRSA)	National Institutes of Health (NIH)
2001	Paul E. Strandjord Young Investigator Award	Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
2004	Faculty Teaching Award	UCSF - Dept. of Laboratory Medicine
2005-2006	Teaching Scholar	TSP Program, UCSF School of Medicine
2009-present	Editorial Board Member (representing Am Society of Hematology), appointed by ASH Presidents	Lab Tests Online (http://labtestsonline.org)
2017	Faculty and Co-Instructor, International Cooperative Leukemia Group & International Cooperative Laboratory of Hematology	Southeast University Medical School, China
2019	Outstanding Contributions to Clinical Chemistry in Education (Award)	AACC (Am Association for Clinical Chemistry) Northern California Section

KEYWORDS/AREAS OF INTEREST

Clinical pathology (laboratory medicine), hematology, coagulation (bleeding and thrombosis), hematopathology (hematopoietic and lymphoid malignancies, including flow cytometry, cytogenetics & molecular diagnostics), clinical chemistry, molecular diagnostics, laboratory automation, translational research, assay development, medical education.

CLINICAL ACTIVITIES

CLINICAL ACTIVITIES SUMMARY

Leadership Activities: (1) I was appointed Chief (CLIA Lab Director), Lab Medicine Service at San Francisco VA Health Care System (SFVAHCS) in July 2017. During the current APM review cycle (2018-present), as the Service Chief and CLIA Lab Director, I continue to direct all laboratory operations including approval of all new tests and testing platforms and standard operation procedures, accreditation and regulatory compliance, quality management, human resource management, budgeting and contracting, etc.; (2) I continue to serve as the Division Chief, Hematology & Hematopathology, and the Division Chief, Clinical Chemistry. Hematology/Hematopathology and Clinical Chemistry are two divisions of Lab Medicine Service at SFVAHCS; (3) In Nov 2019, I was appointed the Facility Lead for the Integrated Diagnostic Service Line (Pathology, Lab Medicine, Radiology) at SFVAHCS. The establishment of Integrated Clinical Service Lines was to ensure standardization for a common Veteran experience, team-based care, rapid communication, resource management, reliable data for quality improvement, and leadership development.

Innovations Activities: (1) During the COVID-19 pandemic (2020), I directed my VA team, along with commercial partners, to quickly validate and bring in two RT-PCR SARS-CoV-2 tests (high-throughput Abbott and rapid Cepheid) in middle March 2020 (the first among all VA Healthcare Systems). In the meantime, started the validation of COVID-19 serology testing in early April and became one of the first VA hospital labs to offer serology testing in May 2020. (2) During 2018-2020, I worked with technical supervisors and validated/approved a numbers of new tests and testing platforms including fecal immunochemical test, procalcitonin, high-sensitivity troponin, BioMerieux Vitek Mass Spectrometry (bacteria, molds, mycobacteria/nocardia), Sebia Capillarys 3 TERA (SPEP/IT, A1c), BindingSite Optilite (free light chains), point-of-care urine toxicology panel, Bio-Rad Geenius HIV1/2, Radiometer ABL90 Flex Plus, Advanced Micro-Osmometer 3320, Alcore ESR, Fentanyl test, etc.

Quality Improvement Activities: As the Service Chief and CLIA Lab Director (SFVAHCS), I am responsible for all Quality Management (QM) activities. Lab Medicine QM Committee meets quarterly to review all quality indicators and take actions as needed. I review and approve all quarterly meeting minutes and annual summary report before submitting to SFVAHCS QM Office.

During the current APM review period (2018-present), had a fully successful CAP Lab Accreditation Inspection (Dec 3, 2019) and served as CAP Inspection Team Leader (2018, 2020).

CLINICAL SERVICES

2017 - present	As the Service Chief (CLIA Lab Director) starting July 2017, I am responsible for the operations of all Divisions in Lab Medicine Service (Hematology/Coagulation, Clinical Chemistry, Blood Bank, Microbiology, Molecular Core Lab, Point-of-Care Testing, Phlebotomy and Central Processing), human resource management (employment of competent qualified personnel), and business management (budgeting and contracting). In the meantime, I continue to serve as the medical director(s) for the Hematology/Hematopathology, Clinical Chemistry, and the Molecular Core divisions in Lab Medicine Service.	12 months per year
2003 - 2017	<p>(1) Chief, Hematology/Coagulation, SFVAHCS (12 months per year): I attended and supervised all activities of the hematology and coagulation laboratories and provide test interpretation and clinical consultation. I am responsible for approval of all new tests and acquisition of new lab equipment in these fields. In addition to hematology and coagulation testing, the lab also performs flow cytometry immunophenotyping for T-cell subsets, fully automated urinalysis, and body fluids analysis. (2) Attending Pathologist, Hematopathology, SFVAHCS (12 months per year): I was responsible for interpretation and report generation of all bone marrow biopsies at SFVAHCS. I also served as an expert consultant to Anatomic Pathology Service and reviewed/signed-out most lymphoma cases. (3) Attending Hematopathologist, UCSFMC (1-2 days per month): I signed-out bone marrow cases at UCSF Moffitt/Long Hospital from 2004-2017. (4) Medical Director, Clinical Chemistry Division, SFVAHCS (12 months per year): Working with the Chief Technologist & Clin Chem Lab Supervisor, I consulted on major activities of the clinical chemistry laboratory including clinical consultation. I reviewed and signed-out all SPEP/IT (Sebia CZE). (5) Clinical Consultation, SFVAHCS (12 months per year): I provided laboratory consultation for hematology, coagulation, hematopathology, urinalysis and clinical chemistry. (6) On-call coverage, SFVAHCS (6 months per year): I provided on-call coverage (nights, weekends, and holidays) for Laboratory Medicine Service including blood bank.</p>	12 months per year

2011 - 2017 Director, Molecular Core Lab, SFVAHCS: I directed all operations of the Molecular Core Lab. The lab brought in the Abbott m2000 molecular diagnostic system in 2011, and real-time PCR based HIV and HCV viral loads and NG/CT tests were performed in-house. HIV differentiation/confirmation assay (Bio-Rad Geenius) was brought in 2017. Abbott Alinity-m brought in 2021. 12 months per year

PROFESSIONAL ACTIVITIES

MEMBERSHIPS

2003 - present Academy of Laboratory Physicians and Scientists (ACLPS)
2003 - present College of American Pathologists (CAP)
2004 - present American Society of Hematology (ASH)
2004 - present American Society of Clinical Pathology (ASCP)
2008 - present American Association for Clinical Chemistry (AACC)
2017 - present Society of Hematopathology (SH)

SERVICE TO PROFESSIONAL ORGANIZATIONS

2004 - present Residents In-Service Exam Committee, Academy of Laboratory Physicians and Scientists (ACLPS) RISE Contributor

2003 - present College of American Pathologists (CAP) Inspector & Inspection Team Leader; Member of the CAP Market Research Panels.

2009 - present Am Society of Hematology (ASH) & Am Association for Clinical Chemistry (AACC) Editorial Board Member for the Lab Tests Online (<http://www.labtestsonline.org>)

SERVICE TO PROFESSIONAL PUBLICATIONS

2005 - present Clinica Chimica Acta, Reviewer

2009 - present ASCP Case Reports (formerly ASCP Check Sample), Reviewer

2009 - present Lab Tests Online (AACC), Editorial Board Member, representing ASH (appointed by the ASH Presidents)

2012 - present Clinical Chemistry, Reviewer

2015 - present Pathology- Research and Practice, Reviewer

2018 - present Cancer Genetics , Reviewer

2019 - present American Journal of Hematology, Reviewer

2020 - present Hematological Oncology, Reviewer

2020 - present The Lancet Respiratory Medicine, Reviewer

2021 - present Journal of Clinical Medicine, Reviewer

INVITED PRESENTATIONS - INTERNATIONAL

- 2007 Advances in Chronic Myeloproliferative Disorders (invited talk). Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
- 2010 An Introduction of US Healthcare Systems and Healthcare Reform (invited talk). Shanghai Jiaotong University, Shanghai, China
- 2012 Pharmacogenetic Testing and Targeted Cancer Therapy (invited talks, sponsored by the Ministry of Education of China), at Harbin Medical University (Harbin), Yunnan University (Kunming), and Chinese Academy of Medical Sciences- Hematology Institute (Tianjin), September 10-19, China
- 2013 Practical Issues and Pitfalls in Diagnosing Eosinophilic Myeloid Disorders (Invited Plenary Lecture). The 10th National Congress on Diagnostic Hematology and the 2013 Summit Forum on Hematologic Disorders, Chinese Society of Hematology, April 26-28, Shanghai, China
- 2013 Pharmacogenetic Testing and Targeted Cancer Treatment (invited talk), Institute of Life Sciences, Southeast University, October 29, Nanjing, China
- 2013 Eosinophilic Myeloid Disorders: An Update on Diagnosis and Classification (invited talk). Department of Hematology, Xiangya Medical College, Central South University, November 1, Changsha, China
- 2015 The Use of Freelite Assays in Uncommon Plasma Cell Neoplasms. The Seventh International Symposium on Clinical Applications of Free Light Chain and Heavy/Light Chain Analysis, April 16-17, Edinburgh, United Kingdom
- 2015 Molecular Genetic Testing in the Diagnosis and Management of Acute and Chronic Myeloid Malignancies. The 2nd International Molecular Pathology Symposium: Cancer Genetics and Diagnostics. Huazhong University of Science and Technology, September 18-20, Wuhan, China
- 2016 Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 22 Cases. European Association for Hematopathology (EAHP) annual meeting, September 3-6, Basel, Switzerland

- 2017 Advances in Benign and Malignant Hematological and Lymphoid Disorders (30hr CME Course), Southeastern University, May 10-19, Nanjing, China
- 2017 2017 Update on Eosinophilic Myeloid Disorders. Tongji Medical College, Huazhong University of Science and Technology, May 21, Wuhan, China
- 2018 Eosinophilic Neoplasms: When to Consider Stem Cell Transplantation? The 3rd Sino-US International Symposium of HSCT and Cancer Immunology. June 1-3, Chongqing, China
- 2018 2018 Update on Primary Eosinophilic Neoplasms. Northwest Hospital, Xi'an Jiaotong University School of Medicine. June 8, Xi'an, China
- 2018 Hypereosinophilia: 2018 Update. Institute of Hematology, Soochow University College of Medicine. September 25, Suzhou, China
- 2018 Hypereosinophilia: 2018 Update. University Hospital, Henan University of Science & Technology. September 28, Luoyang, China
- 2019 Eosinophilic myeloid neoplasm (2019 Update). University Hospital, Dalian Medical University, September 24, Dalian, China

INVITED PRESENTATIONS - NATIONAL

- 2001 PTHrP and PTH Immunoassays. Annual Meeting, Academy of Clinical Laboratory Physicians and Scientists (ACLPS), Seattle, WA
- 2009 PNH Diagnostics Advisory Board Meeting. New York, NY
- 2011 PNH Diagnostics Advisory Board Meeting. Miami, FL
- 2016 The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies- Recommendations for Veterans Healthcare Administration. CAP'16 (College of Am Pathologists), September 25-28, Las Vegas, NV

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

- 1997 Pulmonary hypertension: From Bench to Bedside, UC San Diego Medical Center, San Diego
- 2001 A Mass Spectrometry Based Immunoassay for PTHrP, University of Washington Medical Center, Seattle

2003 Tumor Specific forms of PTHrP: Assay development and identification, VA Medical Center & UCSF, San Francisco, CA

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

2008 The American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA

2009 The American Society of Hematology (ASH) Annual Meeting & Exposition, San Francisco, CA

2010 The American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, FL

2010 The American Society of Clinical Pathology (ASCP) CheckPath (Hematopathology)

2011 The American Society of Clinical Pathology (ASCP) CheckPath (Hematopathology)

2011 The American Society of Hematology (ASH) Annual Meeting & Exposition, San Diego, CA

2012 The American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA

2013 UCSF-CORO (Coro Center for Civic Leadership) Faculty Leadership Collaborative Workshop: Maximizing Leadership Potential, San Francisco, CA

2013 The American Society of Hematology (ASH) Annual Meeting, New Orleans, LA

2014 CAP'14: The Pathologists' Meeting (College of American Pathologists), Chicago, IL

2014 The American Society of Hematology (ASH) Annual Meeting, San Francisco, CA

2015 The American Society of Hematology (ASH) Annual Meeting, Orlando, FL

2016 The American Association for Clinical Chemistry (AACC) Annual Meeting, Philadelphia, PA

2016 The European Association for Hematopathology (EAHP) Annual Meeting, Basel, Switzerland

2016 The American Society of Hematology (ASH) Annual Meeting, San Diego, CA

2017 The American Association for Clinical Chemistry (AACC) Annual Meeting, San Diego, CA

2017 The American Society of Hematology (ASH) Annual Meeting, Atlanta, GA

2018 The American Society of Hematology (ASH) Annual Meeting, San Diego, CA

2019 The American Association for Clinical Chemistry (AACC) Annual Meeting, Anaheim, CA

2019 The American Society of Hematology (ASH) Annual Meeting, Orlando, FL
 2020 Society for Hematopathology 2020 EAHP-SH Annual Meeting, Croatia

GOVERNMENT AND OTHER PROFESSIONAL SERVICE

2003 - present Department of Veterans Affairs Medical Center Staff Physician
 2015 - present Hematopathology Molecular Genomics Committee, VHA Member
 National (Department of Veterans Affairs)
 2015 - present VA Healthcare System, San Francisco Medical Review
 Officer (MRO)
 2014 - present Ad Hoc Expert Review Panel, Chinese Government Panel member for
 Award for Outstanding Self-financed Graduate Students Life Sciences
 Abroad & Chinese Government Scholarship for Foreign
 Graduate Students in China
 2015 - present Overseas Expert Review Panel for the Chang Jiang Panel member for
 Scholar (Full Professor) Recruitment Program, Ministry of Hematology, Lab
 Education (MOE), China Medicine, and
 Pathophysiology

UNIVERSITY AND PUBLIC SERVICE

UCSF CAMPUSWIDE

2003 - present Quality Management Committee, Lab Medicine Service, Member
 VAHCS San Francisco
 2004 - present Transfusion Committee, VAHCS San Francisco Member
 2007 - present Anticoagulation Therapy Committee, VAHCS San Member
 Francisco
 2010 - 2010 Hospital Panel for Urine Toxicology Screen Guide, VAMC Consultant
 2011 - 2011 Hospital Panel for 25(OH) Vitamin D Test Order Guide, Leader
 VAMC
 2015 - present Medical Review Officer (MRO), VAHCS San Francisco the MRO
 2017 - present Medical Executive Committee (MEC), VAHCS San Member
 Francisco
 2017 - present Professional Standards Board (PSB), VAHCS San Member
 Francisco

SCHOOL OF MEDICINE

2012 - 2018 Admissions Committee, School of Medicine Faculty Member
 2019 - present Faculty Mentoring Program Facilitator, Lab
 Medicine Dept.

DEPARTMENTAL SERVICE

2004 - 2017	Lab Medicine Residency Education Committee	Member and Site Director
2004 - 2017	UCSF Hematopathology Fellowship Committee	Member
2007 - 2012	UCSF Clinical Chemistry Fellowship Committee	Member
2005 - 2005	Faculty Search Committee (SFGH Clinical Chemistry Chief)	Member
2007 - present	Appointment, Promotion & Merit (APM) Committee, Dept. of Lab Medicine	Member
2010 - 2010	Faculty Search Committee (VAMC Neuropathologist)	Member
2012 - present	Clinical Competence Committee, Dept. of Lab Medicine	Member
2015 - 2015	Advisory Committee on Compensation, Dept. of Lab Medicine	Member
2018 - 2019	School of Medicine Diversity Leadership Group	Department representative
2019 - present	UCSF Pathology and Lab Medicine Diversity, Equity and Inclusion (DEI) Committee	Member

COMMUNITY AND PUBLIC SERVICE

2009 - present	http://labtestsonline.org (a public resource on diagnostic laboratory testing, more than 4 million visits each month)	Editorial Board Member
2005 - present	Tongji Medical College Overseas Alumni Association (TMCOAA)	Executive Board Member (2005-present), President (2005), Vice President (2012)

CONTRIBUTIONS TO DIVERSITY**CONTRIBUTIONS TO DIVERSITY**

2018-2019: As the department Vice Chair, I was the designated leader for Diversity in the department of Laboratory Medicine. I helped the Chair in creating a culture of diversity and inclusion and in recruiting underrepresented in medicine (UIM) candidates for resident/fellow and faculty positions. I prepared and helped finalizing the annual department Diversity Report to SOM Leadership.

2019-2020: I facilitated the formation of joint Pathology and Lab Medicine departmental Diversity Committee. I am one of the six committee members, representing Department of Lab Medicine

TEACHING AND MENTORING

TEACHING SUMMARY

(1) My ongoing teaching is mostly clinical teaching, i.e. laboratory hematology, coagulation and hematopathology for Clinical Pathology residents and fellows, Hematology/Oncology residents and fellows, and CLS students. (2) I taught 2nd-year medical students as a group discussion leader for the entire M3-Hematology block (2008-2016). (3) Since 2016, I have been teaching the 1st year medical students as a group discussion leader for the ABC-Hematology block. (4) I served as the Site Director of UCSF Lab Medicine Residency Program from 2004-2017. (5) Since its inception in 2008, I have continuously served as the Director of joint SFVA/SFSU Clinical Laboratory Scientist (CLS) Training Program. (6) I have been a member of the Core Competence Committee of the UCSF Lab Medicine Residency Program since 2014.

Additional structured teaching: (1) I taught Internal Medicine residents in the UCSF -VA PRIME Program (2013-2017). (2) I was invited to teach a 45-hour Hematology Course (evening classes) at the SFSU (since Spring 2015), UC Berkeley Extension Program (Spring 2016-Fall 2019), and USF (since Summer 2017).

I am the Mentoring Coordinator for junior faculty (assistant professors), UCSF Department of Laboratory Medicine (since 2017).

RESEARCH AND CREATIVE ACTIVITIES

PEER REVIEWED PUBLICATIONS

1. Lu C, Jin XR. Calcium overload in myocardial ischemia and reperfusion injury. *J Clin Pathophysiol (Guo Wai Yi Yue)*, 1990; 10(4):185-187. (Review)
2. Lu C, Wang DX. Effects of dietary magnesium on pulmonary vascular reactivity and chronic hypoxic pulmonary hypertension. *J Tongji Med Univ*, 1991;11(1): 1-5.
3. Lu C, Wang DX. Effects of dietary oils on pulmonary vascular reactivity and chronic hypoxic pulmonary hypertension. *J Tongji Med Univ*, 1992;12(2): 124-128.
4. Lu C, Wang DX, Yu SB. Effects of acute ingestion of alcohol on pulmonary hypertension: Role of leukotrienes and prostaglandins. 1992; *J Tongji Med Univ*, 12(4): 253-256.
5. Lu C, Wang DX, Yu SB. Different effects of green tea and red tea on pulmonary vascular reactivity and chronic pulmonary hypertension. *Chin J Appl Physiol* 1992; 8: 480-494.
6. Lu C, Wang DX, Yu S. Effect of alcohol ingestion on acute hypoxic pulmonary vasoconstriction in dogs - role of leukotrienes. *Chin J Appl Physiol*, 1992; 8(3): 205-208.
7. Lu C, Wang DX. Dietary oils and experimental pulmonary hypertension. *Chin J Pathophysiol*, 1992; 8(3):234-237.
8. Lu C, Tang CS. Cardionatin and pulmonary hypertension: Pathophysiology and clinical application. *Progress in Physiological Sciences* 1993; 24: 272-275. (Review)
9. Lu C, Tang CS. Interleukin-8 and inflammation: Pathophysiology and implication in cardiovascular disorders. *Progress in Physiological Sciences* 1993; 24: 351-354. (Review)
10. Lu C, Su J, Tang C, Zhou B, Ma D. Protective role of recombinant interleukin-8 on tourniquet shock in rats. *J Beijing Med Univ* 1993; 25(5): 337.

11. Yang YD, Lu C, Wang GC, Zhou AR, Tang J, Gu JR. Expression, isolation and bioactivity recovery of recombinant human VEGF from the prokaryotic expression products in *E. coli*. *High Technology Letters* 1994; 4(3):28-31.
12. Tian Q, Yang Q, Lu CY. A novel hypotensive polypeptide- adrenomedullin. *Sheng Li Ke Xue Jin Zhan (Progress in Physiological Sciences)* 1995; 26:149-151. (Review)
13. Yang Y, Wang G, Lu C, Yang H, Zhu X, Zhou A, Tang J, Ma D. Purification and bioactivity recovery of recombinant human vascular endothelial growth factor from the prokaryotic expression products in *E. coli*. *J Beijing Med Univ* 1994; 26 (suppl.): 89-92.
14. Wang LZ, Lu CY, Su JY, Zhou BH, Ma DL. Therapeutic effect of recombinant IL-8 on experimental shock and its underlying mechanisms. *Clin J Pathophysiol* 1995;11(2):131-134.
15. Lu C, Giordano FJ, Rogers KC, Rothman A. Adenovirus-mediated increase of exogenous and inhibition of endogenous fosB expression in pulmonary arterial smooth muscle cells. *J Mol Cell Cardiol*, 28: 1703-1713, 1996.
16. Wang LZ, Su JY, Lu C, Zhou BH, Ma DL. Effects of recombinant human endothelial-derived interleukin-8 on hemorrhagic shock. *Acta Pharmacologica Sinica*, 18: 434-437, 1997.
17. Lu C, Giordano FJ, Bao X, Morris KC, Rothman A. Antisense fosB RNA inhibits thrombin-induced hypertrophy in cultured pulmonary arterial smooth muscle cells. *Circulation*, 98: 596-603, 1998.
18. Bao X, Lu C, Frangos JA. Temporal gradient in shear but not steady shear stress induces PDGF-A and MCP-1 expression in endothelial cells: Role of NO, NFkB, and egr-1. *Arterioscler Thromb Vasc Biol*, 19: 996-1003, 1999.
19. Bao X, Lu C, Frangos JA. Mechanism of temporal gradients in shear induced ERK1/2 activation and proliferation in endothelial cells. *Am J Physiol*, 281: H22-H29, 2001.
20. Lu CM, Burton DW, Fitzgerald RL, Deftos LJ, Buchholz BA, Vogel JS, Herold DA. Mass spectrometric immunoassay for parathyroid hormone-related protein. *Analytical Chemistry*, 74: 5507-5512, 2002.
21. Sproat LO, Pantanowitz L, Lu CM, Dezube BJ. HIV-associated hemophagocytosis with iron deficiency anemia and massive splenomegaly. *Clin Infect Dis*, 37: e170-e173, 2003.
22. Lu CM, Dezube B, Pantanowitz L. Human immunodeficiency virus infection masquerading as monoclonal gammopathy of undetermined significance. *N Engl J Med*, 349: 1192-1193, 2003.
23. Aslam A, Misbah SA, Pantanowitz L, Lu CM, Dezube BJ. Human immunodeficiency virus infection masquerading as monoclonal gammopathy of undetermined significance. *N Engl J Med*, 349: 2362-2363, 2003.
24. Lu CM. DDK1 in multiple myeloma. *N Engl J Med*, 350: 1464-1466, 2004.
25. Ezzell J, Lu CM, Browne LW, Wang E. Erythrophagocytosis by dysplastic neutrophils in chronic myelomonocytic leukemia and subsequent transformation to acute myeloid leukemia. *Am J Hematol*, 79: 340-342, 2005.
26. Swain R, Miller S, Lu C. Cervicofacial actinomycosis. *ASCP CheckSample Microbiology*, MB05-5 (MB05-330):2005.

27. Lu CM, Murata-Collins JL, Wang E, Siddiqi I, Lawrence HJ. Concurrent Acute Myeloid Leukemia with inv(16)(p13q22)/CBF β -MYH11/Secondary Trisomy 22 and Chronic Lymphocytic Leukemia: Molecular Evidence of Two Separate Diseases. *Am J Hematol*, 81: 963-968, 2006.
28. Lu CM, Wang E, Lawrence HJ. Simultaneous presence of major secondary chromosomal abnormalities in blast crisis of chronic myeloid leukemia. *Cancer Genet Cytogenet*, 172: 174-175, 2007.
29. Lu CM, Wang E. Acute megakaryoblastic leukemia: clinical and pathologic features. *ASCP Check Sample Hematology*, 42 (2):H07-2 (H-309), 2007.
30. J alas J, Wang E, Lu CM. T-cell large granular lymphocyte leukemia and associated pure red cell aplasia. *ASCP Check Sample Hematology*, 42(4):H07-4 (H-311), 2007.
31. Lu CM, Wang E. Juvenile myelomonocytic leukemia. *ASCP Check Sample, Hematology* 43(6):H08-6 (H-321), Aug 2008.
32. Wang E, Lu CM. Refractory cytopenia with multilineage dysplasia and ringed sideroblasts. *ASCP Check Sample Hematology* 43(8):H08-8 (H-323), Oct 2008.
33. J alas J, Wang E, Lu CM. Lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. *ASCP Check Sample, Hematology*, 44(1):H09-1 (H-324), Jan 2009.
34. Bao X, Lu CM, Liu F, Gu Y, Dalton N, Zhu BQ, Foster E, Chen J, Karliner JS, Ross J, Simpson PC, Ziegler MG. Epinephrine is required for normal cardiovascular responses to stress in the phenylethanolamine N-methyltransferase knockout mice. *Circulation*, 116:1024-1031, 2007
35. Pandey S, Herold DA, Lu CM. Measurement of Microalbuminuria Using the Caliper P200 Protein Chip. *Am J Clin Path*, 129(3):432-438, 2008.
36. Bao X, Liu F, Gu Y, Sun P, Lu CM, Ziegler M. Impaired chronotropic response to exercise in mice lacking catecholamines in adrenergic cells. *Ann NY Acad Sci*. 2008 Dec; 1148:297-301. [PMID: 19120121]
37. Hutchinson CB, Lu CM, Wang E. Kikuchi histiocytic necrotizing lymphadenitis. *ASCP Check Sample, Hematology*, 45(1):H10-1 (H-332), Jan 2010.
38. Molofsky AB, Lu CM. Anaplastic large-cell lymphoma, ALK-positive. *ASCP Check Sample, Hematology*, 45(6):H10-6 (H-337), Aug 2010.
39. Wang E, Boswell E, Siddiqi I, Lu CM, Sebastian S, Rehder C, Huang Q. Pseudo-Pelger-Huet anomaly induced by medications. *Am J Clin Pathol* 2011 Feb;135:291 -303.
40. Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, Sebastian S, Rohder C, Lagoo A, Horwitz M, Rizzieri D, Yu JW, Goodman B, Datto M, Buckley P. Donor cell derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: A clinicopathological study of 10 cases and a comprehensive review of the literature. *Am J Clin Pathol* 2011 Apr;135:525-540.
41. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, Hare CB, Deeks SG, Liegler T, Pandori M, Havlir DV, Wong JK. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. *J Virol Methods* 2011 Aug; 175:261-265. [PMID: 21536073]

42. Lu CM, Zhou L, Feng S, Kohn PH, Qi Z, Yu J. Presence of complex t(6;9;22;15) four-way chromosome rearrangements plus a rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia. *Leuk Lymphoma* 2011 Nov; 52:2182-2184. [PMID: 21718138]
43. Lu CM, Zhou L, Wang E, Feng S, Sebastian S, Behler C. Development of refractory anemia with ring sideroblasts and marked thrombocytosis (RARS-T) from RARS through acquisition of Jak2 V617F mutation. *Leuk Lymphoma* 2011 Dec; 52:2405-2407. [PMID: 21806348]
44. Lu CM. Pathology consultation on vitamin D testing: Clinical indications for 25(OH) vitamin D measurement. *Am J Clin Pathol* 2012; 137:831-832. [PMID: 22645788]
45. Alley CL, Wang E, Dunphy CH, Gong JZ, Lu CM, Boswell EL, Burchette J, Lagoo AS. Diagnostic considerations and clinical implications of concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B lymphocytosis: a series of 15 cases review of literature. *Arch Pathol Lab Med* 2013 Apr; 137(4):503-517. [PMID: 23544940]
46. Lu CM. Commentary on clinical case study- A 77-year-old man with bleeding and prolonged aPTT (invited). *Clin Chem* 2012; 58(10):1406-1407. [PMID: 23024129]
47. Cascio M, Lu CM. Serum free light chain analysis and plasma cell neoplasms. *ASCP Check Sample, Hematology*, 48(2):HP13-2 (H-357), March 2013.
48. Reddi DM, Lu CM, Fedoriw G, Liu YC, Wang FF, Ely S, Boswell EL, Louissaint A, Arcasoy MO, Goodman BK, Wang E. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? Clinicopathological study of 41 cases and correlation of cytogenetic features with treatment regimens. *Am J Clin Pathol* 2012; 138(6):855-866. [PMID: 23161720]
49. Wool G, Lu CM. Pathology consultation on anticoagulation monitoring: factor X-related assays (invited review). *Am J Clin Pathol* 2013; 140:623-634. [PMID: 24124140]
50. Wiita AP, Hsu GW, Lu CM, Esensten JH, Wells JA. Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. *Proc Natl Acad Sci USA* 2014 May 27; 111(21):7594-7599. [PMID: 24821784]
51. Wu B, Ingersoll K, Jug R, Lo A, Rehder C, Gong J, Lu CM, Wang E. Myeloid neoplasms following solid organ transplantation: clinicopathologic studies of 23 cases. *Am J Clin Pathol* 2017 Dec 20; 149(1):55-66. [PMID: 29228125]
52. Wang-Rodriguez J, Yunes A, Phan R, Ma N, Baddoura F, Mosse C, Kim AS, Lu CM, Dong DZM, Schichman SA, Icardi M, Ehsan A. The challenges of precision medicine and new advances in molecular diagnostic testing in hematolymphoid malignancies: Impact on the VHA. *Fed Pract.* 2017 Aug;34(Suppl 5):S50-S61. [PMID: 30766310]
53. Yang LH, Su P, Luedke C, Lu CM, Louissaint A, McCall C, Rapisardo S, Vallangeon B, Wang E. Chronic myeloid leukemia following treatment for primary neoplasms or other medical conditions: a report of 21 cases and review of the literature. *Am J Clin Pathol* 2018, Jul 31;150(3):246-258. [PMID: 29992292]
54. Knez V, Liu X, Schowinsky J, Pan ZG, Wang D, Lorsbach R, Lu CM, Luedke C, Wang E, Liang X. Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: A multi-institutional study. *Leukemia & Lymphoma* 2018; Sep 6:1-8 [PMID: 30188223]

55. Liu X, Zhao Y, Luedke C, Jug R, Yang LH, Lu CM, Pan Z, Wang D, Lorsbach R, Shi Y, Knez V, Rehder C, Liang X, Wang E. Infantile Leukemia - What Factors Determine Its Distinct Biological Nature? Clinicopathological Study of 78 Cases. *Int J Lab Hematol*. 2021 Apr 13. doi: 10.1111/ijlh.13540. [PMID: 33847065]
56. Mattis DM, Wang SA, Lu CM. Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia- An ACLPS Critical Review. *Am J Clin Pathol*. 2020 Aug 5; 154(3):305-318. [PMID: 32525541] (invited review)
57. Domeracki S, Clapp RN, Taylor K, Lu CM, Lampiris H, Blanc PD. Cycle Threshold to Test Positivity in COVID-19 for Return to Work Clearance in Health Care Workers. *J Occup Environ Med*. 2020 Nov; 62(11):889-891. [PMID: 32804748]
58. Du J, Chu E, Zhang D, Lu CM, Zhang A, Sha MY. A high-throughput anti-SARS-CoV-2 IgG test platform for COVID-19. *J Virol Methods*. 2021 Jan; 287:114009 [PMID: 33152411]
59. Sun Q, Ren H, Li J, Poster L, Madej R, Loginova Y, Lu CM, Ma Y, Zhang A, Sha M. A highly sensitive and multitarget RT-PCR test for COVID-19. *J Infect Dis* (2020, submitted)
60. Yukl SA, Khan S, Chen TH, Trapecar M, Wu F, Xie G, Telwatte S, Fulop D, Rico AR, Laird GM, Ritter KD, Jones NG, Lu CM, Siliciano RF, Roan NR, Milush JM, Somsouk M, Deeks SG, Hunt PW, Sanjabi S. Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T-cells. *J Virol*. 2020 Dec 22; 95(2):e01331-20. [PMID: 33115867]
61. Ng DL, Goldgof GM, Shy BR ... Lu CM ... Chiu CY. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. *Nature Commun*. 2020 Sep 17; 11(1):4698. [PMID: 32943630]
62. Telwatte S, Kumar N, Vallejo-Gracia A, Kumar GR, Lu CM, Ott M, Wong JK, Yukl SA. Novel RT-ddPCR assays for determining the transcriptional profile of SARS-CoV-2. *J Virologic Methods*. 2021 Jun; 292:114115 (Published online 2021 Mar 2. doi: 10.1016/j.jviromet.2021.114115) [PMID: 33667568]
63. Luedke C, Zhao Y, McCracken J, Maule J, Yang LH, Jug R, Galeotti J, Siddiqi I, Gong J, Lu CM, Wang E. Myeloid Neoplasms in the Setting of Chronic Lymphocytic Leukemia/Chronic Lymphocytic Leukemia-like Disease: A Clinicopathologic Study of 66 Cases Comparing Cases with Prior History of Treatment to Those without. *J Clin Pathol* 2021 Feb 4; *jclinpath-2020-207334*. [PMID: 33542108]
64. Sun Q, Li J, Ren H, Pastor L, Loginova Y, Madej R, Taylor K, Wong J, Zhang Z, Zhang A, Lu CM, Sha MY. Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test. *Plos ONE* 2021; 16(2):e0243183. [PMID; 33621263] (co-corresponding author)

BOOKS AND CHAPTERS

1. Lu CM. Plasma Cell Neoplasms (Including Plasma Cell Myeloma) (Chapter 26; pp. 595-614). In *Practical Lymph Node and Bone Marrow Pathology* (Practical Anatomic Pathology Series book). Springer International, 2020. ISBN 978-3-030-32188-8.
2. Lu CM. Myeloproliferative Neoplasms (chapters). In *Choosing Wisely: Laboratory Tests for Hematologic Neoplasms*. 2020 ed. People's Medical Publishing House (PMPH) Co., Ltd (China).

3. Lu CM. Diagnostic Testing and Medical Decision Making (chapter). In Current Medical Diagnosis and Treatment (CMDT 2020). McGraw Hill. ISBN 978-1-260-45528-1.
4. Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals (chapter). In Current Medical Diagnosis and Treatment (CMDT 2020). McGraw Hill. ISBN 978-1-260-45528-1.
5. Lu CM. Diagnostic Testing and Medical Decision Making (chapter). In Current Medical Diagnosis and Treatment (CMDT 2019). McGraw Hill. ISBN 978-1-260-11743-1.
6. Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals (chapter). In Current Medical Diagnosis and Treatment (CMDT 2019). McGraw Hill. ISBN 978-1-260-11743-1
7. Nicoll D, Lu CM, McPhee S. Guide to Diagnostic Tests, 7th Edition. McGraw Hill 2017 (book) (ISBN-13: 978-1259640896; ISBN-10: 1259640892)
8. Nicoll D, Lu CM. Diagnostic Testing and Medical Decision Making (chapter). In Current Medical Diagnosis and Treatment (CMDT 2018). McGraw Hill Lange (chapter)
9. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals (chapter). In Current Medical Diagnosis and Treatment (CMDT 2018). McGraw Hill Lange
10. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals. Current Medical Diagnosis and Treatment. McGraw Hill LANGE, 2017 (book chapter)
11. Nicoll D, Lu CM. Diagnostic Testing and Medical Decision Making. Current Medical Diagnosis and Treatment (2017). McGraw Hill LANGE (chapter)
12. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals. Current Medical Diagnosis and Treatment. McGraw Hill LANGE, 2016 (book chapter)
13. Nicoll D, Pignone MP, Lu CM. Diagnostic testing and medical decision making. Current Medical Diagnosis and Treatment (2016). McGraw Hill LANGE (chapter)
14. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals. Current Medical Diagnosis and Treatment. McGraw Hill LANGE, 2015 (book chapter)
15. Nicoll D, Pignone MP, Lu CM. Diagnostic testing and medical decision making. Current Medical Diagnosis and Treatment (2015). McGraw Hill LANGE (chapter)
16. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals. Current Medical Diagnosis and Treatment. McGraw Hill LANGE, 2014 (book chapter)
17. Nicoll D, Pignone MP, Lu CM. Diagnostic testing and medical decision making. Current Medical Diagnosis and Treatment (2014). McGraw Hill LANGE (chapter)
18. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals. Current Medical Diagnosis and Treatment. McGraw Hill LANGE, 2013 (book chapter)

19. Nicoll D, Pignone MP, Lu CM. Diagnostic testing and medical decision making. Current Medical Diagnosis and Treatment (2013). McGraw Hill LANGE (chapter)
20. Nicoll D, Lu CM. Appendix: Therapeutic Drug Monitoring, Pharmacogenetic Testing & Laboratory Reference Intervals. Current Medical Diagnosis and Treatment. McGraw Hill LANGE, 2012 (book chapter)
21. Nicoll D, Pignone MP, Lu CM. Diagnostic testing and medical decision making. Current Medical Diagnosis and Treatment (2012). McGraw Hill LANGE (chapter)
22. Nicoll D, Lu CM, Pignone M, McPhee S. Pocket Guide to Diagnostic Tests, 6th Edition. McGraw Hill 2012 (ISBN 978-00071766258). (book)
23. Nicoll D, Lu CM. Appendix: Therapeutic drug monitoring & Laboratory Reference Ranges. 2011 Current Medical Diagnosis and Treatment. McGraw Hill LANGE (chapter)
24. Nicoll D, Pignone MP, Lu CM. Diagnostic testing and medical decision making. 2011 Current Medical Diagnosis and Treatment. McGraw Hill LANGE (chapter)
25. Lu CM. Section VI - Immunophenotyping Markers, 4th Ed. Editor(s): Wu A. Tietz Clinical Guide to Laboratory Tests: WB Saunders Elsevier Inc., Philadelphia. 1633-1711, 2006 (ISBN 978-0-7216-7975-4) (chapter)
26. Lu CM. Flow Cytometric Immunophenotyping, 4th Ed. Editor(s): Wu A. Self -Assessment in Clinical Laboratory Science: AACC Press, Washington, DC, 2008 (chapter)
27. Nicoll D, McPhee S, Pignone M, Lu, CM. Pocket Guide to Diagnostic Tests, 5th Edition. McGraw Hill 2008 (ISBN 978-0-07-148968-3). (book)
28. Lu C. Pulmonary hypertension: pathogenesis and mechanism, 1st Ed. Editor(s): Su JY, Tang CS, Han QD. Cardiovascular Diseases: Pathophysiological Basis and Mechanisms.: Beijing Medical Press, Beijing. 211-231, 1995 (chapter)
29. Lu C. Involvements of vascular smooth muscle cells in the pathogenesis of atherosclerosis, 1st Ed. Editor(s): Su JY, Tang CS, Han QD. Cardiovascular Diseases: Pathophysiologic Basis & Mechanisms.: Beijing Medical Press, Beijing. 38-61, 1995 (chapter)

OTHER PUBLICATIONS

1. Lu CM. Life Stories of My Mentor and Renowned Pathophysiologist Prof. Dixun Wang. In Tongji Stories: Reminiscences on Our Mentors, Schoolmates, and Campus Life (pp. 147-151). TJMCOAA Publishing, Inc. 2019. ISBN 978-0-9831415-8-7.
2. Ng D, Goldgof G, Shy B, ... Lu CM, ... Chiu CY. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. medRxiv. 2020 May 25;2020.05.19.20107482. [PMID: 32511477]
3. Du J, Chu E, Zhang D, Lu CM, Zhang A, Sha MY. A high-throughput anti-SARS-CoV-2 IgG testing platform for COVID-19. medRxiv 2020.07.23.20160804.
4. Sun Q, Li J, Ren H, Pastor L, Loginova Y, Madej R, Taylor K, Wong JK, Zhang A, Lu CM, Sha M. Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test. medRxiv 2020.10.27.20219196. (co-corresponding author)

5. Telwatte S, Kumar N, Vallejo-Garcia A, Kumar GR, Lu VM, Ott M, Wong JK, Yukl SA. Novel RT-ddPCR Assays for determining the transcriptional profile of SARS-CoV-2. *bioRxiv*. 2021 Jan 12:2021.01.12.425991. [PMID: 33469579]
6. Shen S, Fu AY, Jamba M, Li J, Powell MJ, Zhang A, Lu CM, Sha MY. A rapid SARS-CoV-2 variant detection by molecular-clamping based RT-qPCR. *medRxiv* 2021.04.01.21254484;doi: <https://doi-org/10.1101/2021.04.01.21254484>
7. Du J, Zhang D, May H, Loginova Y, Chu C, Madej R, Lu CM, Pathakamuri JA, Kuebler D, Neves J, Zhang A, Sha MY. A Single Drop of Fingertick Blood for Quantitative Antibody Response Evaluation After SARS-CoV-2 Vaccination. *medRxiv* 2021.04.17.21255278; doi: <https://doi.org/10.1101/2021.04.11.21255278>

CONFERENCE ABSTRACTS

1. Lu C, Giordano FJ, Rogers KC, Rothman A "Adenovirus-mediated increase or inhibition of FosB gene expression in pulmonary arterial smooth muscle cells." *Circulation*. Vol. 92 (8, suppl.): I-297, 1995.
2. Lu C, Giordano FJ, Rogers KC, Rothman A. "Antisense fosB RNA inhibits thrombin-induced hypertrophy in cultured pulmonary arterial smooth muscle cells." *Circulation*. Vol. 92 (8, suppl.): I-298, 1995.
3. Lu C, Giordano FJ, Rogers KC, Rothman A. "Role of FosB in cultured pulmonary arterial smooth cell growth." *Circulation*. Vol. 94 (8, suppl.): I-231, 1996.
4. Giordano F.J., Katragadda R., Rothman A., Lu C. "INK4B gene expression induces apoptosis in vascular smooth muscle cells." *Circulation*. Vol. 96 (8, suppl.): I-233, 1997.
5. Lu C., Button D., Wolner B., Bao X., Morris K.C., Giordano F.J., Rothman A. "Distinct intracellular signaling pathways in response to hypertrophic and proliferative stimuli in cultured pulmonary artery smooth muscle cells." *J. Investig. Med*. Vol. 46 (1): 71A, 1998.
6. Zhang L, Lu C, Rothman A. "Cotransfection of FosB and JunB genes induces hypertrophy in cultured pulmonary arterial smooth muscle cells." *J Am Coll Cardiol*. Vol. 33: 224A, 1999.
7. Burton D.W., Jiang P., Xu M., Lu C., Hoffman R.M., Deftos L.J. "PTHrP expression promotes cancer metastases in vivo." *J. Bone. Miner. Res*. Vol. 16 (S193) : F72, 2001.
8. Lu C., Burton D.W., Fitzgerald R.L., Vogel J.S., Buchholz B.A., Tu S.Y., Deftos L.J., Herold D.A. "Application of a 14C-labeled antibody in a two-site immunoassay using accelerator mass spectrometry." *Am. J. Clin. Pathol*. Vol. 116: 282, 2001.
9. Lu C., Scheibel S., Cantor T., Cook D., Wolf P., Gao P. Assessment of N-terminally truncated parathyroid hormone in patients with hyperparathyroidism. *Am. J. Clin. Pathol*. Vol. 116: 284-285, 2001.
10. Pandey S, Herold DA, Lu CM, Phan H, Price K. "Measurement of microalbuminuria using the Caliper P200 protein chip." *LabAutomation 2005, Association for Laboratory Automation*. 01/2005.
11. Bao X, Lu CM, Gu Y, Liu F, Chen J, Simpson PC, Ziegler MG. "Exaggerated blood pressure response to exercise in epinephrine-deficient mice." *The American Society of Human Genetics 55th Annual Meeting, Salt Lake City, October 2005*. 10/2005.

12. Bao X, Lu CM, Kennedy B, Gu Y, Liu F, Ross J, Chen J, Ross J, Ziegler M. "Impaired cardiovascular function in epinephrine-deficient mice." Thirteenth International Symposium of Chromaffin Cell Biology, Pucon, Chile, January 2006. 1/2006.
13. Swain R, Miller S, Lu CM. "Cervicofacial actinomycosis." *Am J Clin Pathol.* Vol. 125: 311, 2006.
14. Bao X, Liu F, Sun P, Lu CM, Simpson PC, Ziegler MG. Impaired chronotropic response to stress in mice lacking catecholamines in adrenergic cells. Ninth Symposium on Catecholamines and Other Neurotransmitters in Stress, Bratislava, Slovakia, June 16-21, 2007.
15. Lu CM, Wang E. Acute megakaryoblastic leukemia: clinical and pathological features. *Am J Clin Pathol.* Vol. 129:329, 2008.
16. J alas J, Wang E, Lu CM. T-cell large granular lymphocytic leukemia and associated pure red cell aplasia. *Am J Clin Pathol.* Vol. 129:330, 2008.
17. Wang E, Lu CM. Juvenile myelomonocytic leukemia. *Am J Clin Pathol.* Vol. 131:286, 2009.
18. Wang E, Lu CM. Refractory anemia with multilineage dysplasia and ringed sideroblasts. *Am J Clin Pathol.* Vol. 131:293, 2009.
19. Boswell E, Lu CM, Huang Q, Wang E. Pseudo Pelger Huet anomaly induced by medications: a comparison of 12 cases with MDS featuring pseudo Pelger-Huet anomaly. Presented at the annual USCAP Meeting, Washington DC, March 20-26, 2010.
20. J alas J, Wang E, Lu CM. Lymphoplasmacytic lymphoma and Waldenstrom's macroglobulinemia. *Am J Clin Pathol.* Vol. 133:501, 2010
21. Wang E, Huang Q, Lu CM, et al. Donor cell-derived MDS and AML after allo-HSCT- a report of 10 cases and review of the literature. Presented at the 52nd ASH annual Meeting, Orlando, FL, Dec 3-7, 2010.
22. Reddi DM, Lu CM, Wang E. Myeloid neoplasms secondary to plasma cell myeloma: clinicopathological study of 11 cases. *Modern Pathology* 2011; 24:403A. Presented at the annual USCAP Meeting, San Antonio, TX, Feb 26-Mar 4, 2011.
23. Hutchinson CB, Lu CM, Wang E. Kikuchi histiocytic necrotizing lymphadenopathy. *Am J Clin Pathol* 135:318-319, 2011.
24. Molofsky AB, Lu CM. Anaplastic large-cell lymphoma, ALK-positive. *Am J Clin Pathol* 135:319-320, 2011.
25. Reddi DM, Boswell EL, Lu CM, Wang E. Plasma cell neoplasm concomitant with myeloid malignancies: clinicopathologic study of 7 cases. Presented at the annual USCAP Meeting, Vancouver, Canada, Mar 17-23, 2012.
26. Reddi DM, Lu CM, Crow JH, Siddiqi IN, Wang E. Congenital leukemia: clinicopathologic study of 4 cases. Presented at the CAP (College of American Pathologists) Meeting, San Diego, Sept 9-12, 2012.
27. Reddi DM, Lu CM, Jerald Gong, Steven Kramer, Wang E. Myeloid neoplasms following solid organ transplantation: clinicopathologic studies of 11 cases. Presented at the annual USCAP Meeting, Baltimore, MD, Mar 2-8, 2013.

28. Lu CM. Practical issues and pitfalls in diagnosing eosinophilic myeloid disorders. Invited plenary lecture, the 10th Nation Congress on Diagnostic Hematology and 2013 Summit Forum on Hematologic Disorders. Shanghai, China, April 25-28, 2013
29. Zhou LK, Liu S, Lu CM, Yao JF, Shen Y, Yang X, Feng SZ, Han MZ. Bone marrow-derived mesenchymal stem cells overexpressing Akt1 protect against ConA-induced liver injury in mice. Presented at the 56th American Society of Hematology (ASH) Annual Meeting, San Francisco, Dec 6-9, 2014.
30. Lu CM. The use of FreeLite assays in uncommon plasma cell neoplasms: bi-clonal plasma cell myeloma and Schnitzler syndrome. *Hematology Reports* 2015;7(s1):59-60. Presented at the 7th International Symposium on Clinical Applications of Free Light Chains and Heavy/Light Chain Analysis, Edinburgh, UK, April 16-17, 2015.
31. Wang E, Lu CM. Myeloid neoplasms following solid organ transplantation: Clinicopathologic studies of 22 cases. 18th Meeting of the European Association for Haematopathology (EAHP), Basel, Switzerland, September 3-8, 2016
32. Wang-Rodriguez J, Lu CM. et al. The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies- Recommendations for Veterans Healthcare Administration. CAP'16 (College of Am Pathologists), Las Vegas, September 25-28, 2016.
33. Lo AE, Lu CM, Jug R, Luedke C, Wang E. Congenital leukemia: clinicopathological study of 5 cases. Presented at the annual USCAP Meeting, San Antonio, TX, Mar 4-7, 2017
34. Liu X, Lu CM, Wang E, et al. Clinicopathological study of 79 cases of infantile leukemia: where should the line for congenital leukemia be drawn for practical purposes. Presented at the annual USCAP Meeting, Vancouver, British Columbia, Canada, Mar 17-23, 2018
35. Saxena K, Vu K, Lu CM, Wang S, Nye HE. Know your ABCDs: Aplasia, Bypass and Copper Deficiency. Presented at the Society of Hospital Medicine's Annual Meeting, Orlando World Center Marriott, Orlando, FL, April 8-11, 2018
36. Yang LH, Luedke C, Jug R, Caleotti J, Takeda M, Siddiqi I, Gong J, Lu CM, Wang E. Myeloid neoplasms arising in chronic lymphocytic leukemia or other indolent B-cell lymphomas in bone marrow: an intrinsic predisposition due to altered microenvironment or a therapy-related direct genetic insult? 19th Meeting of the European Association for Haematopathology (EAHP), Edinburgh, Scotland (UK), September 29-October 4, 2018
37. Jug R, Li Y, Zhou J, Zhang L, Bhargava P, Rapisardo S, Lu CM, Wang E. Potentially de novo Philadelphia chromosome (BCR-ABL1) positive T-ALL/LBL: report of 5 cases in the era of TKI therapy. USCAP annual meeting, National Harbor, Maryland, March 16-21, 2019.
38. Lu CM, Peng Y, Cook S. Ileocecal classic Hodgkin lymphoma versus EBV-positive mucocutaneous ulcer: two overlapping entities. SH-EAHP 2020 meeting, Dubrovnik, Croatia, September 11-16, 2020 (virtual meeting April 2021)
39. Sushama Telwatte, Holly A. Martin, Joseph K. Wong, Chuanyi M. Lu, Sulggi A. Lee, Steven A. Yukl. EXCESS OF SARS-CoV-2 SUBGENOMIC RNAs IN CELLS AND FLUIDS DURING ACUTE INFECTION. Conference on Retroviruses and Opportunistic Infections (CROI) 2021, March 6-10, 2021 (virtual)